COLLEGIUM PHARMACEUTICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.42 USD | +1.62% |
|
+4.54% | +18.32% |
| Apr. 11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
| Feb. 26 | Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating | MT |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Collegium Pharma...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
36.42
USD
Average target price
40
USD
Spread / Average Target
+9.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.32% | 1.19B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024
